Key points – Brentuximab Vedotin and bendamustine regimen is highly active as first salvage therapy in relapsed/refractory HL, with manageable toxicity. The complete response rate of 73.6% exceeded those reported for standard chemotherapy regimens.
Home / Resource Library / Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma